India APIs Incentive Scheme: Will It Galvanize Local Firms, Bridle The Dragon?
Aims To Improve Self-Sufficiency
India shapes new production-linked incentives scheme for critical APIs to ensure self-reliance and cut massive dependence on imports from China, but much will depend on actual implementation, including timely clearances. Pharma will also need to 'walk the talk' alongside.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.
White House directive aimed at reducing dependence on foreign manufacturers for essential medicines and a seemingly more aggressive stance towards site inspections could signal a worrying emerging trend for India pharma. But it also needs to be viewed through the prism of the upcoming US elections and trade tensions with China amid the pandemic.